SciELO - Scientific Electronic Library Online

 
vol.10 número2Esquizofrenia y alteraciones de la percepción visualAcroisquemia asociada a COVID 19 índice de autoresíndice de materiabúsqueda de artículos
Home Pagelista alfabética de revistas  

Servicios Personalizados

Revista

Articulo

Indicadores

  • No hay articulos citadosCitado por SciELO

Links relacionados

  • No hay articulos similaresSimilares en SciELO

Compartir


Revista Virtual de la Sociedad Paraguaya de Medicina Interna

versión On-line ISSN 2312-3893

Resumen

ESCOBAR HERNANDEZ, Johao Emanuel. Heart failure with reduced ejection fraction: common questions in medical practice. Rev. virtual Soc. Parag. Med. Int. [online]. 2023, vol.10, n.2, pp.99-117.  Epub 30-Sep-2023. ISSN 2312-3893.  https://doi.org/10.18004/rvspmi/2312-3893/2023.10.02.99.

Introduction:

Heart failure is a complex clinical syndrome with symptoms and signs resulting from any structural or functional alteration of ventricular filling or blood ejection. The prevalence of heart failure varies from 0.2% to 17.7% in industrialized nations.

Materials and methods:

A review was carried out using databases such as: PubMed, Scopus, Embase, Cochrane Library, Scielo, including observational studies, review articles, clinical trials, and clinical guidelines on the management of patients with heart failure with reduced ejection fraction.

Results and conclusions:

Therapy in heart failure with reduced left ventricular ejection fraction (LVEF) seeks to counteract deleterious counterregulatory mechanisms. Left ventricular systolic dysfunction implies an LVEF ≤ 40%, while heart failure is diagnosed by symptoms and signs of congestion, not LVEF alone. Natriuretic peptides aid in diagnosis, but elevated levels may have non-cardiac causes. Arterial hypotension does not contraindicate the start of pharmacological treatment. Acute kidney injury in these patients indicates a poor prognosis, but Henle loop diuretics may improve renal function. During acute exacerbations of heart failure, recommended medications should not be discontinued, because they reduce mortality and readmissions. Therapies such as ivabradine, digoxin, hydralazine, and isosorbide dinitrate have not demonstrated benefits in heart failure and reduced LVEF. However, vericiguat and omecamtiv mecarbil obtained significant results in reducing deaths and hospitalizations due to HF. Additionally, implantable cardioverter-defibrillator is recommended to prevent sudden cardiac death. The use of mechanical circulatory support and cardiac transplantation should be considered in patients with advanced HF that does not respond adequately to pharmacological treatment.

Palabras clave : heart failure; systolic heart failure; ventricular ejection fraction; stroke volume.

        · resumen en Español     · texto en Español     · Español ( pdf )